Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Chronic Inducible Urticaria (CINDU)
NCT05976243Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of remibrutinib in chronic inducible urticaria (CIndU), sponsored by Novartis. Started Dec 2023; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT05976243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976243.